Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AVDL -25.5% (product revenue guidance), NEOG -4.4%, PSMT -3.2%, TLRY -2.9%, JEF -2.2%, WSC -1.8% (guidance), ASX -0.9% (Dec sales)
Other news:
- IGMS -67.4% (Provides Strategic Update on Autoimmunity Pipeline Programs)
- DYN -5.7% (reports new clinical data showing compelling impact on multiple measures of myotonic dystrophy type 1; Dyne plans to initiate registrational expansion cohort to support potential submission for u.s. accelerated approval for DYNE-101 in DM1 in H1 2026)
- AMLX -4.8% (proposes offering of common stock)
- YMAB -4.5% (provides strategic business update and 2025 priorities)
- NKTR -4.4% (Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis)
- CTNM -2.7% (completes enrollment in Phase 2 PIPE-307 VISTA trial)
- EIX -2.7% (provides update on Southern California wildfires and SCE power outages)
- AMD -1.9% (Biden plans additional round of restrictions on AI chip exports, according to Bloomberg)
- NTLA -1.9% (Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran)
- NVDA -1.5% (Biden plans additional round of restrictions on AI chip exports, according to Bloomberg)
- OMAB -1.3% (Dec traffic)
- BAM -1.1% (announces renewal of normal course issuer bid)
- NGD -1.1% (reports record gold production in Q4)
- MODV -1.1% (raises $105 million in incremental financing backed by stakeholders across the capital structure and takes strategic steps to position business for the future; withdraws guidance)